### LETTER TO THE EDITOR

#### **Cellular and Molecular Life Sciences**



# Reply to Guo's commentary on: "Immune cells lacking Y chromosome show dysregulation of autosomal gene expression"

Lars A. Forsberg<sup>1,2</sup>

Received: 13 September 2021 / Revised: 3 November 2021 / Accepted: 7 November 2021 / Published online: 15 December 2021 © The Author(s) 2021

In a commentary on "Immune cells lacking Y chromosome show dysregulation of autosomal gene expression" [1], Guo provides insightful comments with focus on the role of mosaic loss of chromosome Y (LOY) in Alzheimer's disease (AD). The commentary highlights an emerging view that certain somatic genetic variants detected in blood samples could be associated with disease vulnerability in other organs, including risk for AD in men with LOY in leukocytes [2]. Here, three aspects of recent findings discussed in Gou's commentary are emphasized.

First, an increased risk for disease in men carrying leukocytes without a Y chromosome could be linked with several mechanisms. For example, LOY might directly exacerbate disease progression by impairing normal functions of affected leukocytes. Indeed, LOY-associated transcriptional effects (LATE) have been described on the RNA [1] as well as the protein level [3]. Furthermore, an overlap between germline risk variants for LOY and cancer susceptibility and other conditions suggests that LOY in blood could be viewed as a barometer of genomic imbalance in somatic tissues overall [4]. The relative contribution from direct physiological effects and from a 'common soil' of predisposition,

**Citation of the article commented on**: Dumanski JP, Halvardson J, Davies H, Rychlicka-Buniowska E, Mattisson J, Moghadam BT, Nagy N, Weglarczyk K, Bukowska-Strakova K, Danielsson M, Olszewski P, Piotrowski A, Oerton E, Ambicka A, Przewoznik M, Belch L, Grodzicki T, Chlosta PL, Imreh S, Giedraitis V, Kilander L, Nordlund J, Ameur A, Gyllensten U, Johansson A, Jozkowicz A, Siedlar M, Klich-Raczka A, Jaszczynski J, Enroth S, Baran J, Ingelsson M, Perry JRB, Rys J, Forsberg LA (2021) *Immune cells lacking Y chromosome show dysregulation of autosomal gene expression.* Cell Mol Life Sci **78** (8):4019–4033.

Lars A. Forsberg lars.forsberg@igp.uu.se

<sup>2</sup> The Beijer Laboratory, Uppsala University, Uppsala, Sweden

respectively, is currently evaluated and likely varies in the etiology of different types of LOY-associated disease. In the commentary, Guo highlights the interesting observation that germline risk variants for LOY and AD appear to be largely non-overlapping. Thus, shared genetic predisposition would not likely explain an increased risk for AD among men with LOY in leukocytes.

Furthermore, based on our results that patients with AD and prostate cancer were primarily affected with LOY in natural killer (NK) cells and CD4 + T lymphocytes and granulocytes, respectively [1], Guo suggests that further analysis of NK cells in AD patients and controls will be informative. It should be noted, however, that although these classes of immune cells showed the highest levels of LOY in our analysis, LOY in other types of immune cells might also be relevant for disease vulnerability. To gain further insight into the phenotypical consequences of LOY and associated disease risks, additional functional studies within all relevant subsets of leukocytes will be useful.

In the commentary, Gou also outlines the possible role of LOY within the infection origin theory of AD. Briefly, it is hypothesized that infectious agents would enter the brain at a higher rate among men affected with LOY in peripheral leukocytes, as a consequence of impaired immune functions. In response to this, brain cells would increase production of peptides such as A $\beta$  to fight infections. Hence, aggregation of A $\beta$  and associated chronic inflammation is a hallmark of AD etiology. If proven accurate by studies designed to test this hypothesis, new preventive measures and treatment options could be envisioned to mitigate this detrimental disease.

Author contributions LAF wrote the reply.

**Funding** L.A.F is supported by funding from the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation programme (Grant agreements No. 679744 and 101001789).

<sup>&</sup>lt;sup>1</sup> Department of Immunology, Genetics and Pathology and Science for Life Laboratory, Uppsala University, Uppsala, Sweden

L. A. Forsberg

L.A.F is also supported by grants from the Swedish Research Council (#2017-03762), the Swedish Cancer Society (# 20-1004) and Kjell och Märta Beijers Stiftelse.

Availability of data and material Not applicable.

### Declarations

**Conflict of interest** L.A.F. is cofounder and shareholder in Cray Innovation AB.

Ethics approval and consent to participate Not applicable.

Consent for publication Not applicable.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

## References

 Dumanski JP, Halvardson J, Davies H, Rychlicka-Buniowska E, Mattisson J, Moghadam BT, Nagy N, Weglarczyk K, Bukowska-Strakova K, Danielsson M, Olszewski P, Piotrowski A, Oerton E, Ambicka A, Przewoznik M, Belch L, Grodzicki T, Chlosta PL, Imreh S, Giedraitis V, Kilander L, Nordlund J, Ameur A, Gyllensten U, Johansson A, Jozkowicz A, Siedlar M, Klich-Raczka A, Jaszczynski J, Enroth S, Baran J, Ingelsson M, Perry JRB, Rys J, Forsberg LA (2021) Immune cells lacking Y chromosome show dysregulation of autosomal gene expression. Cell Mol Life Sci 78(8):4019–4033. https://doi.org/10.1007/s00018-021-03822-w

- Dumanski JP, Lambert JC, Rasi C, Giedraitis V, Davies H, Grenier-Boley B, Lindgren CM, Campion D, Dufouil C, Pasquier F, Amouyel P, Lannfelt L, Ingelsson M, Kilander L, Lind L, Forsberg LA, European Alzheimer's Disease Initiative (2016) Mosaic loss of chromosome Y in blood is associated with Alzheimer disease. Am J Hum Genet 98(6):1208–1219. https://doi.org/ 10.1016/j.ajhg.2016.05.014
- Mattisson J, Danielsson M, Hammond M, Davies H, Gallant CJ, Nordlund J, Raine A, Edén M, Kilander L, Ingelsson M, Dumanski JP, Halvardson J, Forsberg LA (2021) Leukocytes with chromosome Y loss have reduced abundance of the cell surface immunoprotein CD99. Sci Rep 11(1):15160. https://doi.org/10.1038/ s41598-021-94588-5
- Thompson DJ, Genovese G, Halvardson J, Ulirsch JC, Wright DJ, 4 Terao C, Davidsson OB, Day FR, Sulem P, Jiang Y, Danielsson M, Davies H, Dennis J, Dunlop MG, Easton DF, Fisher VA, Zink F, Houlston RS, Ingelsson M, Kar S, Kerrison ND, Kinnersley B, Kristjansson RP, Law PJ, Li R, Loveday C, Mattisson J, McCarroll SA, Murakami Y, Murray A, Olszewski P, Rychlicka-Buniowska E, Scott RA, Thorsteinsdottir U, Tomlinson I, Moghadam BT, Turnbull C, Wareham NJ, Gudbjartsson DF, Kamatani Y, Hoffmann ER, Jackson SP, Stefansson K, Auton A, Ong KK, Machiela MJ, Loh PR, Dumanski JP, Chanock SJ, Forsberg LA, Perry JRB, International Lung Cancer C, Breast Cancer Association C, Consortium of Investigators of Modifiers of B, Endometrial Cancer Association C, Ovarian Cancer Association C, Prostate Cancer Association Group to Investigate Cancer Associated Alterations in the Genome C, Kidney Cancer GM-AP, e QC, Biobank-based Integrative Omics Study C, and Me Research T (2019) Genetic predisposition to mosaic Y chromosome loss in blood. Nature 575(7784):652-657. https://doi.org/10.1038/s41586-019-1765-3

**Publisher's Note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.